257 related articles for article (PubMed ID: 23260199)
41. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.
Bower K; Napier CE; Cole SL; Dagg RA; Lau LM; Duncan EL; Moy EL; Reddel RR
PLoS One; 2012; 7(11):e50062. PubMed ID: 23185534
[TBL] [Abstract][Full Text] [Related]
42. Telomere maintenance in sarcomas.
Johnson JE; Broccoli D
Curr Opin Oncol; 2007 Jul; 19(4):377-82. PubMed ID: 17545803
[TBL] [Abstract][Full Text] [Related]
43. Augmented telomerase activity, reduced telomere length and the presence of alternative lengthening of telomere in renal cell carcinoma: plausible predictive and diagnostic markers.
Pal D; Sharma U; Khajuria R; Singh SK; Kakkar N; Prasad R
Gene; 2015 May; 562(2):145-51. PubMed ID: 25769384
[TBL] [Abstract][Full Text] [Related]
44. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
45. Telomere-maintenance mechanisms in soft-tissue malignant fibrous histiocytomas.
Matsuo T; Shay JW; Wright WE; Hiyama E; Shimose S; Kubo T; Sugita T; Yasunaga Y; Ochi M
J Bone Joint Surg Am; 2009 Apr; 91(4):928-37. PubMed ID: 19339578
[TBL] [Abstract][Full Text] [Related]
46. Presence of alternative lengthening of telomeres associated circular extrachromosome telomere repeats in primary leukemia cells of chronic myeloid leukemia.
Samassekou O; Malina A; Hébert J; Yan J
J Hematol Oncol; 2013 Apr; 6():26. PubMed ID: 23547895
[TBL] [Abstract][Full Text] [Related]
47. Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.
Gao J; Pickett HA
Nat Rev Cancer; 2022 Sep; 22(9):515-532. PubMed ID: 35790854
[TBL] [Abstract][Full Text] [Related]
48. Disease mutant analysis identifies a new function of DAXX in telomerase regulation and telomere maintenance.
Tang M; Li Y; Zhang Y; Chen Y; Huang W; Wang D; Zaug AJ; Liu D; Zhao Y; Cech TR; Ma W; Songyang Z
J Cell Sci; 2015 Jan; 128(2):331-41. PubMed ID: 25416818
[TBL] [Abstract][Full Text] [Related]
49. SLX4IP Antagonizes Promiscuous BLM Activity during ALT Maintenance.
Panier S; Maric M; Hewitt G; Mason-Osann E; Gali H; Dai A; Labadorf A; Guervilly JH; Ruis P; Segura-Bayona S; Belan O; Marzec P; Gaillard PL; Flynn RL; Boulton SJ
Mol Cell; 2019 Oct; 76(1):27-43.e11. PubMed ID: 31447390
[TBL] [Abstract][Full Text] [Related]
50. Oncogenic herpesvirus KSHV triggers hallmarks of alternative lengthening of telomeres.
Lippert TP; Marzec P; Idilli AI; Sarek G; Vancevska A; Bower M; Farrell PJ; Ojala PM; Feldhahn N; Boulton SJ
Nat Commun; 2021 Jan; 12(1):512. PubMed ID: 33479235
[TBL] [Abstract][Full Text] [Related]
51. Single-Molecule Telomere Assay via Optical Mapping (SMTA-OM) Can Potentially Define the ALT Positivity of Cancer.
Raseley K; Jinwala Z; Zhang D; Xiao M
Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372458
[TBL] [Abstract][Full Text] [Related]
52. Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers.
Henson JD; Reddel RR
FEBS Lett; 2010 Sep; 584(17):3800-11. PubMed ID: 20542034
[TBL] [Abstract][Full Text] [Related]
53. Telomerase activity and telomere length in primary and metastatic tumors from pediatric bone cancer patients.
Sotillo-Piñeiro E; Sierrasesúmaga L; Patiñno-García A
Pediatr Res; 2004 Feb; 55(2):231-5. PubMed ID: 14630995
[TBL] [Abstract][Full Text] [Related]
54. Alternative Lengthening of Telomeres (ALT) in Tumors and Pluripotent Stem Cells.
Zhao S; Wang F; Liu L
Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31835618
[TBL] [Abstract][Full Text] [Related]
55. [Telomere Recombination in Normal Mammalian Cells].
Zhdanova NS; Rubtsov NB
Genetika; 2016 Jan; 52(1):14-23. PubMed ID: 27183789
[TBL] [Abstract][Full Text] [Related]
56. Alternative Lengthening of Telomeres in the Budding Yeast
Cohn M; Andersson AK; Mateo RQ; Möller MC
G3 (Bethesda); 2019 Oct; 9(10):3345-3358. PubMed ID: 31427453
[TBL] [Abstract][Full Text] [Related]
57. Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically.
Montgomery E; Argani P; Hicks JL; DeMarzo AM; Meeker AK
Am J Pathol; 2004 May; 164(5):1523-9. PubMed ID: 15111298
[TBL] [Abstract][Full Text] [Related]
58. Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.
Alzoubi H; Minasi S; Gianno F; Antonelli M; Belardinilli F; Giangaspero F; Jaffrain-Rea ML; Buttarelli FR
Endocr Pathol; 2022 Dec; 33(4):494-505. PubMed ID: 34993885
[TBL] [Abstract][Full Text] [Related]
59. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.
Heaphy CM; Subhawong AP; Hong SM; Goggins MG; Montgomery EA; Gabrielson E; Netto GJ; Epstein JI; Lotan TL; Westra WH; Shih IeM; Iacobuzio-Donahue CA; Maitra A; Li QK; Eberhart CG; Taube JM; Rakheja D; Kurman RJ; Wu TC; Roden RB; Argani P; De Marzo AM; Terracciano L; Torbenson M; Meeker AK
Am J Pathol; 2011 Oct; 179(4):1608-15. PubMed ID: 21888887
[TBL] [Abstract][Full Text] [Related]
60. Alternative paths to telomere elongation.
Lee JJ; Lee J; Lee H
Semin Cell Dev Biol; 2021 May; 113():88-96. PubMed ID: 33293233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]